Rabbit Anti-Human FABP4
Slide this table
Cat-Nr. | 102-PA134S |
Size | 100 µg |
Price | 175 € |
Category | Polyclonal Antibody |
Clone Nr. | Rabbit IgG |
Species Reactivity | Human |
Formulation | lyophilized |
Buffer | PBS |
Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
Preparation | Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant human FABP4. |
Antigen | Recombinant human FABP4 (RT #400-018) |
Application | WB |
Synonyms | Adipocyte lipid-binding protein, Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, A-FABP, AFABP |
Description | Fatty acid binding protein 4 (FABP4), also known as adipocyte P2 and A FABP (adipocyte FABP), is a FABP family member that is expressed in adipocytes and monocyte derived foam cells. It is a lipid transport protein that binds long chain fatty acid and retinoic acid. Human and mouse FABP4 share a 91% amino acid sequence homology. FABP4 plays an important role in maintaining glucose and lipid homeostasis and has been primarily regarded as an adipocyte- and macrophage-specific protein. However recent studies suggest that it may be more widely expressed. A strong FABP4 expression was found in endothelial cells (ECs) of capillaries and small veins in several mouse and human tissues, including the heart and kidney. FABP4 was also detected in the ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy and ECs. In most of these cases, FABP4 was detected in both the nucleus and cytoplasm. FABP4 mRNA and protein levels were significantly induced in cultured ECs by VEGF-A and bFGF treatment. The effect of VEGF-A on FABP4 expression was inhibited by chemical inhibition or short-hairpin (sh) RNA-mediated knockdown of VEGFR-2 (KDR), whereas the VEGFR1 agonists, PlGF-1 and PlGF-2, had no effect on FABP4 expression. Knockdown of FABP4 in ECs significantly reduced proliferation both under baseline conditions and in response to VEGF and bFGF. Thus, FABP4 emerged as a novel target of the VEGF/VEGFR-2 pathway and a positive regulator of cell proliferation in ECs. |
Uniprot ID | P15090 |
Protein RefSeq | NP_001433.1 |
mRNA RefSeq | NM_001442.2 |
Figures

Western Blot analysis of recombinant human FABP4 [Cat# 400-018] and human FABP5 [Cat# 400-024] using a rabbit polyclonal anti-human FABP4 antibody [Cat# 102-PA134]. There is no cross reactivity with FABP5 visible. [WB: AP-conjugated secondary antibody].

Double IF staining of human FABP4 and CD31 in a coculture of HDLECs and C2C12 cells with a polyclonal rabbit anti-human FABP4 antibody [Cat# 102-PA134; Protein-A purified] and a monoclonal mouse anti-human CD31 antibody [Cat# 101-M92]. Conjugated secondary antibodies: goat anti-rabbit ALEXA Flour 488 (1:600) [Dianova], goat anti-mouse PE (1:400) [Santa Cruz].

Immunofluorescence staining of FABP4 in primary human dermal microvascular endothelial cells (HDMEC) with anti-human FABP4 (10 µg/ml) [Cat# 102-PA134] and counter staining of nuclei with Dapi. As secondary antibody goat anti-rabbit ALEXA Flour 488 (Dianova) was used 1:600.
NOTE: The antibody seems to detect solely the lymphatic ECs and not the blood ECs. (Upper panel: 200X; Lower panel: 400X)
All prices plus VAT + possible delivery charges